A phase I dose escalation study (NCT02157051) was performed in HER2- BC patients (25% being TNBC), where a Type I T-cell response was measured.120 A phase II study investigating STEMVAC in early-stage TNBC is currently recruiting patients (NCT05455658). Here, ERBB2 is linked to breast cancer.